JP2013500715A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013500715A5 JP2013500715A5 JP2012522925A JP2012522925A JP2013500715A5 JP 2013500715 A5 JP2013500715 A5 JP 2013500715A5 JP 2012522925 A JP2012522925 A JP 2012522925A JP 2012522925 A JP2012522925 A JP 2012522925A JP 2013500715 A5 JP2013500715 A5 JP 2013500715A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding fragment
- chain variable
- antibody
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 14
- 102000036639 antigens Human genes 0.000 claims 14
- 108091007433 antigens Proteins 0.000 claims 14
- 239000012634 fragment Substances 0.000 claims 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 208000015181 infectious disease Diseases 0.000 claims 7
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 5
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 239000001963 growth medium Substances 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- 241000709721 Hepatovirus A Species 0.000 claims 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 claims 1
- 241000701806 Human papillomavirus Species 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23033209P | 2009-07-31 | 2009-07-31 | |
| US61/230,332 | 2009-07-31 | ||
| US25761209P | 2009-11-03 | 2009-11-03 | |
| US61/257,612 | 2009-11-03 | ||
| PCT/US2010/043182 WO2011014438A1 (en) | 2009-07-31 | 2010-07-26 | Fully human antibodies to btla |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013500715A JP2013500715A (ja) | 2013-01-10 |
| JP2013500715A5 true JP2013500715A5 (enExample) | 2013-08-08 |
| JP5898617B2 JP5898617B2 (ja) | 2016-04-06 |
Family
ID=42830274
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012522925A Active JP5898617B2 (ja) | 2009-07-31 | 2010-07-26 | Ｂｔｌａに対する完全ヒト抗体 |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US8563694B2 (enExample) |
| EP (2) | EP3199551A3 (enExample) |
| JP (1) | JP5898617B2 (enExample) |
| KR (1) | KR20120090037A (enExample) |
| CN (1) | CN102762593B (enExample) |
| AR (1) | AR077594A1 (enExample) |
| AU (1) | AU2010276580A1 (enExample) |
| BR (1) | BR112012007875A2 (enExample) |
| CA (1) | CA2769473A1 (enExample) |
| CL (1) | CL2012000254A1 (enExample) |
| CO (1) | CO6612216A2 (enExample) |
| EA (1) | EA201270228A1 (enExample) |
| IL (1) | IL217793A0 (enExample) |
| IN (1) | IN2012DN00863A (enExample) |
| MX (1) | MX2012001417A (enExample) |
| SG (1) | SG177689A1 (enExample) |
| TW (1) | TW201121564A (enExample) |
| WO (1) | WO2011014438A1 (enExample) |
| ZA (1) | ZA201200732B (enExample) |
Families Citing this family (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2769473A1 (en) | 2009-07-31 | 2011-02-03 | N.V. Organon | Fully human antibodies to btla |
| CN103732626A (zh) * | 2011-06-13 | 2014-04-16 | 艾比吉诺米克斯合作公司 | 抗psgl-1抗体及其用途 |
| US10005839B2 (en) * | 2013-05-17 | 2018-06-26 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Antagonist of the BTLA/HVEM interaction for use in therapy |
| CN105682683A (zh) | 2013-08-02 | 2016-06-15 | 阿杜罗生物科技控股有限公司 | 结合cd27激动剂以及免疫检查点抑制以用于免疫刺激 |
| CA2920539C (en) | 2013-08-08 | 2024-01-02 | Cytune Pharma | Combined pharmaceutical composition |
| KR102364523B1 (ko) | 2013-08-08 | 2022-02-18 | 싸이튠 파마 | Ｉｌ―１５ 및 ｉｌ―１５ｒ 알파 스시 도메인 기반 모듈로카인 |
| US10759863B2 (en) | 2013-09-05 | 2020-09-01 | Sanford Burnham Prebys Medical Discovery Institute | Modulation of γδ T cells |
| WO2016146143A1 (en) | 2015-03-16 | 2016-09-22 | Amal Therapeutics Sa | Cell penetrating peptides and complexes comprising the same |
| JP2018521959A (ja) * | 2015-04-29 | 2018-08-09 | サンフォード−バーナム メディカル リサーチ インスティテュート | Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション |
| JP2018515138A (ja) | 2015-05-06 | 2018-06-14 | エスエヌアイピーアール・テクノロジーズ・リミテッドＳｎｉｐｒ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ | 微生物集団の改変および微生物相の修飾 |
| SG10201913567QA (en) | 2015-06-30 | 2020-02-27 | Sanford Burnham Med Res Inst | Btla fusion protein agonists and uses thereof |
| AU2016316730B2 (en) | 2015-09-02 | 2023-05-25 | Immutep S.A.S. | Anti-LAG-3 Antibodies |
| US10149887B2 (en) | 2015-10-23 | 2018-12-11 | Canbas Co., Ltd. | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment |
| RS63125B1 (sr) | 2015-11-03 | 2022-05-31 | Janssen Biotech Inc | Antitela koja se specifično vezuju za pd-1 i njihova upotreba |
| AU2016349632A1 (en) | 2015-11-07 | 2018-05-24 | Multivir Inc. | Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer |
| KR102815803B1 (ko) * | 2015-12-02 | 2025-06-05 | 주식회사 에스티사이언스 | 당화된 btla(b- 및 t-림프구 약화인자)에 특이적인 항체 |
| EP3419999B1 (en) | 2016-02-26 | 2021-08-04 | (INSERM) Institut National de la Santé et de la Recherche Médicale | Antibodies having specificity for btla and uses thereof |
| WO2017160599A1 (en) | 2016-03-14 | 2017-09-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of cd300b antagonists to treat sepsis and septic shock |
| RU2748378C2 (ru) | 2016-03-16 | 2021-05-25 | Амаль Терапьютикс Са | Комбинация модулятора иммунных контрольных точек и комплекса, содержащего проникающий в клетку пептид, карго-молекулу и пептидный агонист tlr, для применения в медицине |
| US20190298824A1 (en) | 2016-05-04 | 2019-10-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv | Albumin-binding immunomodulatory compositions and methods of use thereof |
| WO2017205875A1 (en) | 2016-05-27 | 2017-11-30 | Dnatrix, Inc. | Adenovirus and immunomodulator combination therapy |
| GB201609811D0 (en) | 2016-06-05 | 2016-07-20 | Snipr Technologies Ltd | Methods, cells, systems, arrays, RNA and kits |
| IL263834B2 (en) | 2016-06-20 | 2024-01-01 | Kymab Ltd | Anti-pd-l1 antibodies |
| IL317989A (en) | 2016-08-17 | 2025-02-01 | Compugen Ltd | Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof |
| DK3515476T3 (da) | 2016-09-21 | 2024-09-02 | Amal Therapeutics Sa | Fusion der omfatter et cellepenetrerende peptid, en multiepitop og en trl-peptidagnost til behandlingen af cancer |
| EP3518946A4 (en) | 2016-09-27 | 2020-09-09 | Board of Regents, The University of Texas System | METHODS TO IMPROVE IMMUNE CHECKPOINT BLOCKING TREATMENT BY MODULATING THE MICROBIOME |
| WO2018071668A1 (en) | 2016-10-12 | 2018-04-19 | Board Of Regents, The University Of Texas System | Methods and compositions for tusc2 immunotherapy |
| CA3042698A1 (en) | 2016-11-04 | 2018-05-11 | Aximmune, Inc. | Beta-alethine, immune modulators, and uses thereof |
| BR112019010878A2 (pt) | 2016-11-29 | 2019-10-01 | Lindhofer Horst | combinação de anticorpos multifuncionais de redirecionamento de células t com moduladores de ponto de verificação imunológico e usos dos mesmos |
| AU2017375958A1 (en) | 2016-12-12 | 2019-07-04 | Multivir Inc. | Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases |
| CN108264557B (zh) * | 2016-12-30 | 2021-08-24 | 惠和生物技术(上海)有限公司 | 一种结合cd3和t细胞负共刺激分子的双功能分子及其应用 |
| TWI788340B (zh) * | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
| BR112019022009A2 (pt) | 2017-04-21 | 2020-05-12 | Sillajen, Inc. | Terapia de combinação de vírus vaccinia oncolítico e inibidor de ponto de verificação |
| EP3618866A4 (en) * | 2017-05-02 | 2021-07-14 | Merck Sharp & Dohme Corp. | STABLE FORMULATIONS OF ANTI-CTLA4 ANTIBODIES ALONE AND IN COMBINATION WITH PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHOD OF USING THEREOF |
| JOP20190261A1 (ar) | 2017-05-19 | 2019-11-05 | Lilly Co Eli | أجسام مضادة لعامل مساعد لـ btla واستخداماتها |
| JP7678493B2 (ja) | 2017-05-29 | 2025-05-16 | エクセリクシス， インク． | 癌関連免疫抑制阻害剤 |
| US12215151B2 (en) | 2017-05-31 | 2025-02-04 | Stcube & Co., Inc. | Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1 |
| US11542331B2 (en) | 2017-06-06 | 2023-01-03 | Stcube & Co., Inc. | Methods of treating cancer using antibodies and molecules that bind to BTN1A1 or BTN1A1-ligands |
| BR112019024291A2 (pt) | 2017-06-09 | 2020-07-28 | Providence Health & Services-Oregon | utilização de cd39 e de cd103 para a identificação de células t tumorais humanas reativas para o tratamento do câncer |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| WO2019165195A1 (en) | 2018-02-22 | 2019-08-29 | Srivastava Satish | Combination therapy for the treatment of cancer |
| EP3758732B1 (en) | 2018-02-27 | 2024-07-24 | Leidos, Inc. | Pd-1 peptide inhibitors |
| EP3768698B1 (en) | 2018-03-19 | 2025-02-12 | MultiVir Inc. | Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer |
| US10760075B2 (en) | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
| KR20210006344A (ko) | 2018-03-25 | 2021-01-18 | 에스엔아이피알 바이옴 에이피에스. | 미생물 감염의 치료 및 예방 |
| WO2019211370A1 (en) | 2018-05-03 | 2019-11-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating cancer |
| US20210251994A1 (en) | 2018-06-15 | 2021-08-19 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
| CN118459590A (zh) | 2018-08-01 | 2024-08-09 | 感应检查疗法公司 | 抗btn3a抗体及其在治疗癌症或感染性病症中的用途 |
| CN110790837A (zh) | 2018-08-02 | 2020-02-14 | 上海君实生物医药科技股份有限公司 | 抗btla抗体 |
| GB201820554D0 (en) * | 2018-12-17 | 2019-01-30 | Univ Oxford Innovation Ltd | BTLA antibodies |
| CA3123338A1 (en) | 2018-12-21 | 2020-06-25 | Ose Immunotherapeutics | Bifunctional anti-pd-1/il-7 molecule |
| US12247075B2 (en) | 2018-12-26 | 2025-03-11 | Imcheck Therapeutics Sas | BTN3A binding proteins and uses thereof |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| US11384146B2 (en) | 2019-04-01 | 2022-07-12 | Curia Ip Holdings, Llc | BTLA-binding antibodies for modulating immune response and treating disease |
| EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| EP4054591A1 (en) | 2019-11-04 | 2022-09-14 | Astrazeneca AB | Combination therapy for treating cancer |
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
| KR20220114063A (ko) | 2019-12-13 | 2022-08-17 | 큐진 인크. | 신규한 인터루킨-15 (ｉｌ-15) 융합 단백질 및 이의 용도 |
| US20230114107A1 (en) | 2019-12-17 | 2023-04-13 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| TW202136287A (zh) | 2019-12-17 | 2021-10-01 | 法商Ｏｓｅ免疫治療公司 | 包含il-7變體之雙官能分子 |
| CN113134081A (zh) * | 2020-01-20 | 2021-07-20 | 上海君实生物医药科技股份有限公司 | 抗btla抗体药物组合物及其用途 |
| US20230279116A1 (en) | 2020-06-03 | 2023-09-07 | Mv Biotherapeutics Sa | Combination of an atp-hydrolyzing enzyme and an immune checkpoint modulator and uses thereof |
| EP4161952A1 (en) | 2020-06-04 | 2023-04-12 | Leidos, Inc. | Immunomodulatory compounds |
| GB202008860D0 (en) * | 2020-06-11 | 2020-07-29 | Univ Oxford Innovation Ltd | BTLA antibodies |
| CN116096906A (zh) | 2020-06-29 | 2023-05-09 | 旗舰创业创新五公司 | 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途 |
| EP4178611A1 (en) | 2020-07-07 | 2023-05-17 | BioNTech SE | Therapeutic rna for hpv-positive cancer |
| AU2021361844A1 (en) | 2020-10-12 | 2023-06-15 | Leidos, Inc. | Immunomodulatory peptides |
| KR20230096024A (ko) * | 2020-10-23 | 2023-06-29 | 아납티스바이오, 아이엔씨. | B 및 t 림프구 약화인자 (btla) 조절제 및 이의 사용 방법 |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| WO2022212784A1 (en) | 2021-03-31 | 2022-10-06 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| EP4320156A1 (en) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| AU2022253351A1 (en) | 2021-04-09 | 2023-10-12 | Boehringer Ingelheim International Gmbh | New scaffold for bifunctional molecules with improved properties |
| KR20240049794A (ko) | 2021-06-07 | 2024-04-17 | 프로비던스 헬스 앤드 서비시즈 - 오레곤 | Cxcr5, pd-1, 및 icos 발현 종양 반응성 cd4 t 세포 및 그의 용도 |
| US20240316104A1 (en) | 2021-06-29 | 2024-09-26 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| EP4370552A1 (en) | 2021-07-13 | 2024-05-22 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| EP4469558A1 (en) * | 2022-01-29 | 2024-12-04 | HiFiBiO, Inc. | Anti-btla antibodies and uses thereof in treating cancer |
| EP4469482A1 (en) * | 2022-01-29 | 2024-12-04 | HiFiBiO, Inc. | Antibody against btla and uses thereof |
| EP4482859A1 (en) | 2022-02-27 | 2025-01-01 | Boehringer Ingelheim International GmbH | Bispecific antibodies against cd277 and a tumor-antigen |
| EP4490191A1 (en) | 2022-03-08 | 2025-01-15 | Alentis Therapeutics AG | Use of anti-claudin-1 antibodies to increase t cell availability |
| PE20251671A1 (es) | 2022-03-15 | 2025-06-30 | Compugen Ltd | Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia de combinacion en el tratamiento del cancer |
| US20230322929A1 (en) * | 2022-04-12 | 2023-10-12 | Shanghai Junshi Biosciences Co., Ltd. | Compositions and Methods for Treating Solid Tumors with Anti-BTLA as Mono or Combination Therapy |
| JP2025515337A (ja) * | 2022-04-27 | 2025-05-14 | アナプティスバイオ インコーポレイティッド | Ｂ及びｔリンパ球アテニュエータ（ｂｔｌａ）調節因子及びその使用方法 |
| GB202209518D0 (en) | 2022-06-29 | 2022-08-10 | Snipr Biome Aps | Treating & preventing E coli infections |
| CN120322455A (zh) * | 2022-07-19 | 2025-07-15 | 舒泰神(加州)生物科技有限公司 | 特异性识别b和t淋巴细胞衰减器(btla)的抗体及其应用 |
| WO2024028386A1 (en) | 2022-08-02 | 2024-02-08 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| EP4598946A1 (en) | 2022-10-05 | 2025-08-13 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| EP4608390A1 (en) | 2022-10-24 | 2025-09-03 | Cancer Research Technology Limited | Tumour sensitisation to checkpoint inhibitors with redox status modifier |
| WO2024089417A1 (en) | 2022-10-24 | 2024-05-02 | Memorial Sloan-Kettering Cancer Center | Tumour stratification for responsiveness to an immune checkpoint inhibitor |
| WO2024118923A2 (en) * | 2022-12-02 | 2024-06-06 | Eli Lilly And Company | Btla agonist antibodies and uses thereof |
| IL321098A (en) | 2022-12-14 | 2025-07-01 | Astellas Pharma Europe Bv | Combination therapy including bispecific binding agents that bind to CLDN18.2- and CD3- and immune checkpoint inhibitors |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| EP4649173A1 (en) | 2023-01-13 | 2025-11-19 | Akrivia Biomedics Limited | Method of profiling diseases |
| AU2024254671A1 (en) | 2023-03-30 | 2025-10-02 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| WO2024200823A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof |
| WO2024243594A1 (en) * | 2023-05-25 | 2024-11-28 | Anaptysbio, Inc. | Btla agonist for mudulation of dendritic cells |
| TW202515608A (zh) | 2023-06-26 | 2025-04-16 | 以色列商坎布根有限公司 | Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途 |
| WO2025121445A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025242835A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
| WO2025250011A1 (en) | 2024-05-29 | 2025-12-04 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Treatment for cancer |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| EP0216846B2 (en) | 1985-04-01 | 1995-04-26 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| WO1988001649A1 (en) | 1986-09-02 | 1988-03-10 | Genex Corporation | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| WO1988009344A1 (en) | 1987-05-21 | 1988-12-01 | Creative Biomolecules, Inc. | Targeted multifunctional proteins |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| WO1990006952A1 (fr) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Facteur de stimulation de colonies de granulocytes modifies chimiquement |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| AU2235992A (en) | 1991-06-14 | 1993-01-12 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
| DK0617706T3 (da) | 1991-11-25 | 2001-11-12 | Enzon Inc | Multivalente antigenbindende proteiner |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US6129914A (en) | 1992-03-27 | 2000-10-10 | Protein Design Labs, Inc. | Bispecific antibody effective to treat B-cell lymphoma and cell line |
| WO1993022332A2 (en) | 1992-04-24 | 1993-11-11 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US5368854A (en) | 1992-08-20 | 1994-11-29 | Schering Corporation | Use of IL-10 to treat inflammatory bowel disease |
| DE69330523T4 (de) | 1992-08-21 | 2012-08-23 | Vrije Universiteit Brussel | Immunoglobuline ohne leichte ketten |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| EP0754225A4 (en) | 1993-04-26 | 2001-01-31 | Genpharm Int | HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS |
| DK0698097T3 (da) | 1993-04-29 | 2001-10-08 | Unilever Nv | Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5532210A (en) | 1994-06-08 | 1996-07-02 | E. I. Du Pont De Nemours And Company | High temperature superconductor dielectric slow wave structures for accelerators and traveling wave tubes |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| WO1997003715A1 (en) | 1995-07-21 | 1997-02-06 | The General Hospital Corporation | Method and apparatus of enhancing the delivery of a pharmaceutical formulation |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| GB2339430A (en) | 1997-05-21 | 2000-01-26 | Biovation Ltd | Method for the production of non-immunogenic proteins |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| PT2180007E (pt) | 1998-04-20 | 2013-11-25 | Roche Glycart Ag | Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| US6326482B1 (en) | 1999-04-23 | 2001-12-04 | Genentech, Inc. | SH2 domain-containing peptides |
| GB9818110D0 (en) | 1998-08-19 | 1998-10-14 | Weston Medical Ltd | Needleless injectors and other devices |
| US6096002A (en) | 1998-11-18 | 2000-08-01 | Bioject, Inc. | NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method |
| JP2002531466A (ja) | 1998-12-01 | 2002-09-24 | プロテイン デザイン ラブス， インコーポレイテッド | γ−インターフェロンに対するヒト化抗体 |
| MXPA01005778A (es) | 1998-12-09 | 2003-07-21 | Dow Chemical Co | Un metodo para fabricar glicoproteinas que tienen glicosilacion de tipo humano. |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| KR20060067983A (ko) | 1999-01-15 | 2006-06-20 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| US7632983B2 (en) | 2000-07-31 | 2009-12-15 | Biolex Therapeutics, Inc. | Expression of monoclonal antibodies in duckweed |
| EP1324779B1 (en) | 2000-09-29 | 2011-07-20 | Schering Corporation | Pegylated interleukin-10 |
| EP1443961B1 (en) | 2001-10-25 | 2009-05-06 | Genentech, Inc. | Glycoprotein compositions |
| CA2462653C (en) | 2001-11-07 | 2016-06-07 | Aya Jakobovits | Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer |
| ES2197003B1 (es) | 2002-04-08 | 2005-03-16 | J. URIACH & CIA S.A. | Nuevos compuestos antagonistas de integrinas alfa. |
| EA200401325A1 (ru) | 2002-04-09 | 2005-04-28 | Киова Хакко Когио Ко., Лтд. | Клетки с модифицированным геномом |
| US20070134247A9 (en) | 2002-04-12 | 2007-06-14 | Ramot At Tel Aviv University Ltd. | Prevention of brain inflammation as a result of induced autoimmune response |
| WO2007001459A2 (en) * | 2004-11-15 | 2007-01-04 | Washington University | Compositions and methods for modulating lymphocyte activity |
| US20040071694A1 (en) | 2002-10-14 | 2004-04-15 | Devries Peter J. | Erythropoietin receptor binding antibodies |
| CA2508375C (en) * | 2002-12-02 | 2014-05-27 | Abgenix, Inc. | Antibodies directed to tumor necrosis factor and uses thereof |
| EP1591527B1 (en) | 2003-01-23 | 2015-08-26 | Ono Pharmaceutical Co., Ltd. | Substance specific to human pd-1 |
| US7410483B2 (en) | 2003-05-23 | 2008-08-12 | Novare Surgical Systems, Inc. | Hand-actuated device for remote manipulation of a grasping tool |
| JPWO2005007800A1 (ja) * | 2003-07-18 | 2007-04-12 | 持田製薬株式会社 | 抗血小板膜糖蛋白質ｖｉモノクローナル抗体 |
| US20110142858A1 (en) | 2004-06-07 | 2011-06-16 | Ramot At Tel Aviv University Ltd. | Method of Passsive Immunization Against Disease or Disorder Charcterized by Amyloid Aggregation with Diminished Risk of Neuroinflammation |
| MX2007005612A (es) * | 2004-11-12 | 2007-08-14 | Genentech Inc | Novedosas composiciones y metodos para el tratamiento de enfermedades inmuno relacionadas. |
| US8349320B2 (en) * | 2004-12-09 | 2013-01-08 | La Jolla Institute For Allergy And Immunology | Compositions and methods for modulating responses mediated or associated with BTLA activity |
| CA2598454C (en) | 2005-02-18 | 2013-04-09 | Medarex, Inc. | Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues |
| CA2614320A1 (en) | 2005-07-07 | 2007-01-18 | Coley Pharmaceutical Group, Inc. | Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment |
| BRPI0620601A2 (pt) | 2005-12-08 | 2011-11-16 | Medarex Inc | anticorpo monoclonal humano isolado ou uma porção ligante ao antìgeno do mesmo, composição, imunoconjugado, molécula de ácido nucléico isolada, vetor de expressão, célula hospedeira, método para preparar um anticorpo anti-o8e e método para tratar ou prevenir uma doença definida pelo crescimento de células tumorais expressando o8e |
| AR063840A1 (es) * | 2006-11-15 | 2009-02-25 | Medarex Inc | Anticuerpos humanos monoclonales para btla y metodos de uso |
| CA2706926A1 (en) | 2007-11-30 | 2009-06-11 | Bristol-Myers Squibb Company | Anti-b7h4 monoclonal antibody-drug conjugate and methods of use |
| CA2769473A1 (en) | 2009-07-31 | 2011-02-03 | N.V. Organon | Fully human antibodies to btla |
-
2010
- 2010-07-26 CA CA2769473A patent/CA2769473A1/en not_active Abandoned
- 2010-07-26 AU AU2010276580A patent/AU2010276580A1/en not_active Abandoned
- 2010-07-26 JP JP2012522925A patent/JP5898617B2/ja active Active
- 2010-07-26 EP EP16203147.0A patent/EP3199551A3/en not_active Withdrawn
- 2010-07-26 US US13/388,028 patent/US8563694B2/en active Active
- 2010-07-26 AR ARP100102698A patent/AR077594A1/es not_active Application Discontinuation
- 2010-07-26 WO PCT/US2010/043182 patent/WO2011014438A1/en not_active Ceased
- 2010-07-26 SG SG2012003406A patent/SG177689A1/en unknown
- 2010-07-26 KR KR1020127005168A patent/KR20120090037A/ko not_active Withdrawn
- 2010-07-26 EA EA201270228A patent/EA201270228A1/ru unknown
- 2010-07-26 BR BR112012007875A patent/BR112012007875A2/pt not_active IP Right Cessation
- 2010-07-26 EP EP10737222A patent/EP2459594A1/en not_active Withdrawn
- 2010-07-26 IN IN863DEN2012 patent/IN2012DN00863A/en unknown
- 2010-07-26 MX MX2012001417A patent/MX2012001417A/es not_active Application Discontinuation
- 2010-07-26 CN CN201080045118.6A patent/CN102762593B/zh active Active
- 2010-07-27 TW TW099124759A patent/TW201121564A/zh unknown
-
2012
- 2012-01-26 IL IL217793A patent/IL217793A0/en unknown
- 2012-01-30 ZA ZA2012/00732A patent/ZA201200732B/en unknown
- 2012-01-31 CL CL2012000254A patent/CL2012000254A1/es unknown
- 2012-02-22 CO CO12031267A patent/CO6612216A2/es not_active Application Discontinuation
-
2013
- 2013-09-19 US US14/031,319 patent/US9346882B2/en active Active
-
2016
- 2016-04-14 US US15/098,627 patent/US10155813B2/en active Active
-
2018
- 2018-10-31 US US16/176,335 patent/US20190119381A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013500715A5 (enExample) | ||
| JP2012254092A5 (enExample) | ||
| FI3348571T3 (fi) | Yksidomeeninen vasta-aine ohjelmoitu solukuolema -ligandille (pd-l1) ja siitä peräisin oleva proteiini | |
| JP2022079549A5 (enExample) | ||
| JP2019533989A5 (ja) | 抗ｐｄ−１抗体及びその使用 | |
| RU2018146050A (ru) | Биспецифические связывающие белки, которые связывают иммуномодулирующий белок и опухолевый антиген | |
| JP2017526350A5 (enExample) | ||
| JP2019523221A5 (enExample) | ||
| IL256871B2 (en) | Constructs for bispecific antibodies binding dll3 and cd3 and uses thereof | |
| JP2021502104A5 (enExample) | ||
| JP2017114866A5 (enExample) | ||
| JP2017523786A5 (enExample) | ||
| RU2019110835A (ru) | Антитела к pd-1(cd279) | |
| JP2012530496A5 (enExample) | ||
| JP2015146822A5 (enExample) | ||
| JP2020503001A5 (enExample) | ||
| JP2016511750A5 (enExample) | ||
| JP2014221064A5 (enExample) | ||
| JP2016519651A5 (enExample) | ||
| SI2686347T1 (en) | Antibodies against CD70 | |
| JP2017163973A5 (enExample) | ||
| JP2012143232A5 (enExample) | ||
| JP2014509837A5 (enExample) | ||
| JP2018527919A5 (enExample) | ||
| JP2011527902A5 (enExample) |